Final answer:
The most common secondary malignancies affecting patients treated for Hodgkin's disease, especially with chemotherapy and radiation, include acute myeloid leukemia, breast cancer, non-small cell lung cancer, bladder cancer, melanoma, and non-Hodgkin's lymphoma.
Step-by-step explanation:
Common Secondary Malignancies in Hodgkin's Disease Survivors:
Patients previously treated for Hodgkin's disease (HL) with chemotherapy and radiation are at risk for several types of secondary malignancies. Among these are acute myeloid leukemia (AML), which is one of the most common secondary cancers following HL treatment, especially within the first 10 years post-therapy. Additionally, survivors have an increased risk for solid tumors, which may manifest much later, often several decades post-treatment. Notable solid tumors include breast cancer, non-small cell lung cancer, bladder cancer, and melanoma. It's also important to consider non-Hodgkin's lymphoma (NHL) as another potential secondary malignancy. These secondary malignancies are associated with the long-term effects of treatment regimens such as the MOPP regimen (mechlorethamine, vincristine, procarbazine, and prednisone), which was historically used to treat Hodgkin's disease.